Disease Areas
News and analysis on disease research and diagnostics.
Cornell University Licenses UBR5 Inhibitor Program to Bridge Medicines
The New York-based drugmaker will further develop the anti-UBR5 molecules for treatment-resistant TNBC and ovarian cancers
In Brief This Week: Day One, Sophia Genetics, Genetron Health, Global Cancer Technology
News items for the week of July 26, 2021.
The drug, MS21, has shown preclinically to inhibit growth of tumor cells with mutations in the PI3K/PTEN/AKT pathway.
Gilead Sciences Q2 Revenues Grow 21 Percent as CAR T-Cell Business Jumps 39 Percent
Revenues from pharmaceutical products were almost entirely driven by the COVID-19 treatment remdesivir, though sales of Kite Pharma's CAR T-cell therapies grew, too.
Researchers Look to Validate Promising Immunotherapy Response Biomarker in Early-Stage Breast Cancer
Premium
MHC-II expression could be useful for guiding neoadjuvant immunotherapy in HER2-negative breast cancers, according to findings in Clinical Cancer Research.
Jul 29, 2021
Merck Q2 Revenues Grow 22 Percent
Jul 29, 2021
AstraZeneca Q2 Revenues Increase 31 Percent
Jul 28, 2021
Pfizer Nearly Doubles Q2 Revenues
Jul 28, 2021
Bristol Myers Squibb Q2 Revenues Grow 16 Percent
Jul 28, 2021
Strata Oncology Raises $90M in Series C Financing
Jul 28, 2021
Jul 27, 2021
Kiromic BioPharma Acquires InSilico Solutions
Jul 27, 2021